Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Maraviroc. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 known ✓ | P51681 | 20/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | KCNE1 | P15382 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | KCNQ1 | P51787 | 1/20 | 1.00 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maraviroc SCHEMBL20451355 | 1.00 | CCR5 (1.00) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| Maraviroc SCHEMBL4576508 | 1.00 | CCR5 (1.00) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| Maraviroc SCHEMBL334506 | 1.00 | CCR5 (1.00) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| Maraviroc SCHEMBL2177194 | 1.00 | CCR5 (1.00) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| Maraviroc SCHEMBL51991 | 1.00 | CCR5 (1.00) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| Maraviroc SCHEMBL12611449 | 1.00 | CCR5 (1.00) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| Maraviroc SCHEMBL12611504 | 0.95 | CCR5 (0.91) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| Maraviroc SCHEMBL30852775 | 0.95 | CCR5 (0.91) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| Maraviroc SCHEMBL12611605 | 0.95 | CCR5 (0.91) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| Maraviroc SCHEMBL14168620 | 0.94 | CCR5 (0.89) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1937639-B1 | PYRIDINAMINOSULFONYL SUBSTITUTED BENZAMIDES AS INHIBITORS OF CYTOCHROME P450 3A4 (CYP3A4) | PFIZER PROD INC (US) | 2010-03-03 | — | — | EP | claimed |
| EP-1937639-A2 | PYRIDINAMINOSULFONYL SUBSTITUTED BENZAMIDES AS INHIBITORS OF CYTOCHROME P450 3A4 (CYP3A4) | Pfizer Products Incorporated (US) | 2008-07-02 | — | — | EP | claimed |
| WO-2007034312-A2 | PYRIDINAMINOSULFONYL SUBSTITUTED BENZAMIDES AS INHIBITORS OF CYTOCHROME P450 3A4 (CYP3A4) | PFIZER PRODUCTS INC. (US) | 2007-03-29 | — | — | WO | claimed |
| EP-2640729-B1 | INHIBITORS OF HIV REPLICATION | VIIV HEALTHCARE UK LTD (GB) | 2016-12-21 | — | — | EP | disclosed |
| US-20160355528-A1 | INHIBITORS OF HIV REPLICATION | VIIV HEALTHCARE UK LIMITED (GB) | 2016-12-08 | — | — | US | disclosed |
| US-9447116-B2 | Inhibitors of HIV replication | VIIV HEALTHCARE UK LIMITED (GB) | 2016-09-20 | — | — | US | disclosed |
| US-20150336965-A1 | NOVEL ANTIVIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2015-11-26 | — | — | US | disclosed |
| US-9132129-B2 | Antiviral compounds | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2015-09-15 | — | — | US | disclosed |
| US-20140315927-A1 | Inhibitors of HIV Replication | VIIV HEALTHCARE UK LIMITED (GB) | 2014-10-23 | — | — | US | disclosed |
| US-8809363-B2 | Inhibitors of HIV replication | VIIV HEALTHCARE UK LIMITED (GB) | 2014-08-19 | — | — | US | disclosed |
| US-8779143-B2 | Crystalline forms of maraviroc phosphate and process for maraviroc amorphous form | HETERO RESEARCH FOUNDATION (IN) | 2014-07-15 | — | — | US | disclosed |
| WO-2008099278-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR CCR5 ANTAGONISTS | PFIZER LIMITED (GN) | 2008-08-21 | — | — | WO | disclosed |
| EP-1937639-A2 | PYRIDINAMINOSULFONYL SUBSTITUTED BENZAMIDES AS INHIBITORS OF CYTOCHROME P450 3A4 (CYP3A4) | Pfizer Products Incorporated (US) | 2008-07-02 | — | — | EP | disclosed |
| US-20080021011-A1 | THERAPEUTIC COMPOUNDS | PFIZER INC | 2008-01-24 | — | — | US | disclosed |
| WO-2008004096-A1 | PYRAZOLE DERIVATIVES AS CYTOCHROME P450 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2008-01-10 | — | — | WO | disclosed |
| WO-2008004100-A2 | THERAPEUTIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2008-01-10 | — | — | WO | disclosed |
| WO-2007144720-A2 | CCR5 ANTAGONIST FOR ENHANCING IMMUNE RECONSTITUTION AND TREATING OPPORTUNISTIC INFECTION IN HIV PATIENTS | PFIZER PRODUCTS INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| US-20070167497-A1 | Therapeutic Compounds | PFIZER INC | 2007-07-19 | — | — | US | disclosed |
| US-20070099915-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER INC. | 2007-05-03 | — | — | US | disclosed |
| WO-2007034312-A2 | PYRIDINAMINOSULFONYL SUBSTITUTED BENZAMIDES AS INHIBITORS OF CYTOCHROME P450 3A4 (CYP3A4) | PFIZER PRODUCTS INC. (US) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160355528-A1 | INHIBITORS OF HIV REPLICATION | RTF2, POLRMT, MAVS | CCR5 139/4885KCNH2 4630/4885CYP3A4 1489/4885 |
| US-20070099915-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | IMPDH1, INTS9, TYMP | CCR5 267/4885KCNH2 4108/4885CYP3A4 28/4885 |
| US-20080021011-A1 | THERAPEUTIC COMPOUNDS | SLC10A1, PCSK9, CFTR | CCR5 776/4885KCNH2 1716/4885CYP3A4 152/4885 |
| US-20150336965-A1 | NOVEL ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | CCR5 25/4885KCNH2 4125/4885CYP3A4 742/4885 |
| US-20140315927-A1 | Inhibitors of HIV Replication | RTF2, POLRMT, MAVS | CCR5 139/4885KCNH2 4630/4885CYP3A4 1489/4885 |
| US-20070167497-A1 | Therapeutic Compounds | SLC10A1, PCSK9, CFTR | CCR5 776/4885KCNH2 1716/4885CYP3A4 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.